野村发表研究报告指,药明生物(02269.HK) 去年下半年收入按年增长17%至118亿元人民币(下同),盈利按年增长38%至25.7亿元,符合公司早前公布的盈利预告。期内毛利率及经营利润率分别为48.7%及33.7%,按年扩阔6.1及6.7个百分点,为过去三年最高水平,主要受惠销售组合改善及产能利用率提升。按业务划分,去年下半年非IND及后期服务/商业化生产收入按年分别增长29.4%及27.7%...
Source Link野村发表研究报告指,药明生物(02269.HK) 去年下半年收入按年增长17%至118亿元人民币(下同),盈利按年增长38%至25.7亿元,符合公司早前公布的盈利预告。期内毛利率及经营利润率分别为48.7%及33.7%,按年扩阔6.1及6.7个百分点,为过去三年最高水平,主要受惠销售组合改善及产能利用率提升。按业务划分,去年下半年非IND及后期服务/商业化生产收入按年分别增长29.4%及27.7%...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.